Jun 2026 (Q2 FY26) — Aug 4, 2026
Revvity Q2 FY26 — Strong Diagnostics and AI-Driven Life Sciences Demand Drive Raised Full-Year Outlook
Read the full callRevvity (RVTY) earnings
- Jul 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Revvity earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 730 | +1.3% YoY | Quarterly, as filed | Quarter to Jul 2026 | Revenue from operations as filed. |
| Operating margin | 12.2 | −0.4 pts YoY | Operating profit / revenue | Quarter to Jul 2026 | For the quarter; a change is in percentage points. |
| Net profit | 51.8 | −3.9% YoY | Quarterly, as filed | Quarter to Jul 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
32 of 33 judged targets kept · 13 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| China immunodiagnostics divestiture: definitive agreement | expect to reach a definitive agreement within the next 2 months | Mar 2026 | We have now signed a definitive agreement with the buyer on terms consistent with our initial expectations and we continue to anticipate the transaction closing by the end of 2027. | Achieved |
| Full-year adjusted EPS | $5.35 to $5.45 | Dec 2025 | This all results in us now expecting that our adjusted earnings per share this year will be in the range of $5.30 to $5.40, up $0.10 from our prior outlook. | Revised Up |
| Full-year adjusted tax rate baseline | 18% baseline | Sep 2025 | our full year adjusted tax rate assumption also remains unchanged at approximately 18% | On Track |
1 of REVVITY, INC.'s 46 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 43 more targets are in the full ledger.
Claimed
- Pro forma organic growth of 3% in Q2, exceeding the high end of expectations.
- Pro forma adjusted EPS of $1.41, well above guidance due to operational performance, tax timing, and tariff refunds.
- Diagnostics segment grew 11% organically in Q2, with Reproductive Health in mid-teens and Immunodiagnostics (ex-China) in high single digits.
- Full-year organic growth guidance raised to 4%-5% from 3%-4%.
- Net debt to adjusted EBITDA leverage ratio reduced to 2.5x, targeting gross leverage below 3x by year-end.
Qualified
- Signals software business organic revenue declined approximately 20% year-over-year in Q2 due to difficult comps and contract timing.
- Life Sciences segment experienced a 3% organic decline in Q2, primarily due to software comps and latent TB pressures.
- Instrument order velocity for high-content screening outpaced near-term production capacity, leaving some incremental upside on the table in Q2.
- Americas region experienced a low single-digit decline due to software comps and continued latent TB pressures.
Price
$150.94 −1.11% · −$1.7
Performance +61.6% 1Y
1Y: $93.42 on 17 Oct 2025 → $150.94. High $157.36 (5 Oct 2026), low $82.26 (29 Apr 2026).
- Previous close
- $152.64
- 52-week range
- $82.26 – $157.36
- One year
- +58.37%
Overview
- Symbol
- RVTY
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
32 of 33 judged targets kept · 13 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| China immunodiagnostics divestiture: definitive agreement | expect to reach a definitive agreement within the next 2 months | Mar 2026 | We have now signed a definitive agreement with the buyer on terms consistent with our initial expectations and we continue to anticipate the transaction closing by the end of 2027. | Achieved |
| Full-year adjusted EPS | $5.35 to $5.45 | Dec 2025 | This all results in us now expecting that our adjusted earnings per share this year will be in the range of $5.30 to $5.40, up $0.10 from our prior outlook. | Revised Up |
| Full-year adjusted tax rate baseline | 18% baseline | Sep 2025 | our full year adjusted tax rate assumption also remains unchanged at approximately 18% | On Track |
Claimed
- Pro forma organic growth of 3% in Q2, exceeding the high end of expectations.
- Pro forma adjusted EPS of $1.41, well above guidance due to operational performance, tax timing, and tariff refunds.
- Diagnostics segment grew 11% organically in Q2, with Reproductive Health in mid-teens and Immunodiagnostics (ex-China) in high single digits.
- Full-year organic growth guidance raised to 4%-5% from 3%-4%.
- Net debt to adjusted EBITDA leverage ratio reduced to 2.5x, targeting gross leverage below 3x by year-end.
Qualified
- Signals software business organic revenue declined approximately 20% year-over-year in Q2 due to difficult comps and contract timing.
- Life Sciences segment experienced a 3% organic decline in Q2, primarily due to software comps and latent TB pressures.
- Instrument order velocity for high-content screening outpaced near-term production capacity, leaving some incremental upside on the table in Q2.
- Americas region experienced a low single-digit decline due to software comps and continued latent TB pressures.
The full ledger
Open REVVITY, INC.’s full ledger
A free account opens 5 company ledgers a month. All 46 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 5, 2026
Revvity Q1 FY26 — Strong Organic Growth and Strategic Divestiture
Read the full callEvery analysed call
Revvity earnings calls (RVTY)
Financials
What the filings say
Net profit, year on year: −4% (quarter to jul 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 684 | 729 | 665 | 720 | 699 | 772 | 711 | 730 |
| Operating profit | 98 | 119 | 72 | 91 | 82 | 112 | 76 | 89 |
| Operating margin | 14.3% | 16.3% | 10.9% | 12.6% | 11.7% | 14.5% | 10.7% | 12.2% |
| Other income | 2 | -24 | -20 | -22 | -26 | -20 | -26 | -26 |
| Interest | 24 | 23 | 23 | 23 | 23 | 24 | 25 | 23 |
| Profit before tax | 100 | 95 | 52 | 69 | 56 | 92 | 50 | 64 |
| Tax rate | 7.0% | 6.5% | 20.4% | 19.6% | 15.2% | −4.6% | 18.2% | 15.8% |
| Net profit | 94 | 95 | 42 | 54 | 47 | 98 | 41 | 52 |
| EPS ($ per share) | 0.77 | — | 0.35 | 0.46 | 0.40 | — | 0.36 | 0.47 |
| Line item | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 111 | 111 | 112 | 126 | 126 | 123 | 121 | 112 |
| Reserves | 2,602 | 2,812 | 3,507 | 4,417 | 4,951 | 5,609 | 5,845 | 6,054 |
| Total liabilities | 3,391 | 3,725 | 4,225 | 7,859 | 6,747 | 5,692 | 4,726 | 4,918 |
| Fixed assets | 319 | 318 | 368 | 486 | 483 | 510 | 482 | 479 |
| Investments | — | — | — | — | 0 | 690 | 0 | — |
| Total assets | 5,976 | 6,539 | 7,960 | 15,001 | 14,130 | 13,565 | 12,392 | 12,168 |
| Line item | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 311 | 363 | 892 | 1,411 | 680 | 91 | 628 | 583 |
| Cash from investing | -160 | -488 | -504 | -4,113 | -133 | 1,314 | 776 | -17 |
| Cash from financing | -179 | -150 | -203 | 2,942 | -662 | -947 | -1,128 | -858 |
| Net cash flow | -36 | 26 | 211 | 217 | -149 | 444 | 250 | -243 |
| Capital expenditure | -93 | -76 | -64 | -86 | -86 | -81 | -87 | -74 |
| Free cash flow | 218 | 287 | 829 | 1,325 | 594 | 10 | 542 | 509 |
RVTY revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | FY2027 | Q2 FY2027 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | — | 54% | 49% | 49% | 51% | 51% | 49% | 51% | +4.7% |
| Life Sciences | — | 46% | 51% | 51% | 49% | 49% | 51% | 49% | -2.0% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2027 · share of revenue
- Americas 45%
- Europe 31% ↑ 5 pt
- Asia 24% ↓ 5 pt
As RVTY cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
69 filings between Oct 29, 2025 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$5.97M
17 sales by 7 insiders
94% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 24
- Award — granted as compensation
- 4
- Option exercise — converted options into shares
- 15
- Tax withheld — shares kept back by the company to cover tax
Also filed: 9 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Singh Prahlad R. | — | $2.56M | Feb 5, 2026 |
| Vohra Tajinder S | — | $1.63M | Sep 16, 2026 |
| Goldberg Joel S | — | $1.27M | Feb 5, 2026 |
| Krakowiak Maxwell | — | $235.7K | Sep 21, 2026 |
| Victor Miriame | — | $180.9K | Feb 24, 2026 |
| McMurry-Heath Michelle | — | $58.4K | Feb 23, 2026 |
| Gonzales Anita | — | $29.8K | Oct 1, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Gonzales Anita VP and CAO | Sale 10b5-1 plan | 84 | $13.1K |
| Sep 21, 2026 | Krakowiak Maxwell Please See Remarks | Sale 10b5-1 plan | 1,631 | $235.7K |
| Sep 16, 2026 | Vohra Tajinder S Please See Remarks | Sale 10b5-1 plan | 7,330 | $1.03M |
| Aug 25, 2026 | MICHAS ALEXIS P Director | Gift | 285 | $0 |
| Aug 14, 2026 | Goldberg Joel S Please See Remarks | Gift | 27,785 | $0 |
| Aug 14, 2026 | Goldberg Joel S Please See Remarks | Gift | 27,785 | $0 |
| Aug 13, 2026 | Singh Prahlad R. Please See Remarks | Gift | 7,636 | $0 |
| Aug 13, 2026 | Singh Prahlad R. Please See Remarks | Gift | 59,650 | $0 |
| Aug 13, 2026 | Singh Prahlad R. Please See Remarks | Gift | 59,650 | $0 |
| Aug 13, 2026 | Singh Prahlad R. Please See Remarks | Gift | 7,636 | $0 |
| Jul 20, 2026 | Gonzales Anita Vice President and CAO | Sale 10b5-1 plan | 85 | $9.3K |
| Jun 15, 2026 | Gonzales Anita Vice President and CAO | Tax withheld | 33 | $3.3K |
| May 7, 2026 | Vounatsos Michel Director | Award | 1,015 | $0 |
| May 7, 2026 | McMurry-Heath Michelle Director | Award | 1,265 | $0 |
| May 7, 2026 | Barrett Peter Director | Award | 1,265 | $0 |
| May 7, 2026 | Witz Pascale Director | Award | 1,015 | $0 |
| May 7, 2026 | MICHAS ALEXIS P Director | Award | 1,217 | $0 |
| May 7, 2026 | McMurry-Heath Michelle Director | Award | 1,015 | $0 |
| May 7, 2026 | Vandebroek Sophie V. Director | Award | 1,015 | $0 |
| May 7, 2026 | Klobuchar Michael A Director | Award | 1,015 | $0 |
| May 7, 2026 | Witney Frank Director | Award | 1,265 | $0 |
| May 7, 2026 | MICHAS ALEXIS P Director | Award | 1,467 | $0 |
| May 7, 2026 | Vandebroek Sophie V. Director | Award | 1,265 | $0 |
| May 7, 2026 | Chapin Samuel R. Director | Award | 1,265 | $0 |
| May 7, 2026 | Witney Frank Director | Award | 1,015 | $0 |
| May 7, 2026 | Witz Pascale Director | Award | 1,265 | $0 |
| May 7, 2026 | Chapin Samuel R. Director | Award | 1,015 | $0 |
| May 7, 2026 | Vounatsos Michel Director | Award | 1,265 | $0 |
| May 7, 2026 | Barrett Peter Director | Award | 1,015 | $0 |
| May 7, 2026 | Klobuchar Michael A Director | Award | 1,265 | $0 |
| Apr 20, 2026 | Gonzales Anita Vice President and CAO | Sale 10b5-1 plan | 80 | $7.4K |
| Mar 16, 2026 | Gonzales Anita Please See Remarks | Award | 1,600 | $0 |
| Mar 6, 2026 | Gonzales Anita Please See Remarks | Award | 1,721 | $0 |
| Feb 24, 2026 | Victor Miriame Please See Remarks | Sale 10b5-1 plan | 1,862 | $180.9K |
| Feb 24, 2026 | Victor Miriame Please See Remarks | Option exercise 10b5-1 plan | 1,862 | $178.3K |
| Feb 23, 2026 | McMurry-Heath Michelle Director | Sale | 600 | $58.4K |
| Feb 17, 2026 | Singh Prahlad R. Please See Remarks | Tax withheld | 6,901 | $662.7K |
| Feb 17, 2026 | Goldberg Joel S Please See Remarks | Tax withheld | 1,733 | $166.4K |
| Feb 17, 2026 | Krakowiak Maxwell Please See Remarks | Tax withheld | 902 | $86.6K |
| Feb 17, 2026 | Krakowiak Maxwell Please See Remarks | Tax withheld | 1,457 | $139.9K |
| Feb 17, 2026 | Gonzales Anita Please See Remarks | Tax withheld | 85 | $8.2K |
| Feb 17, 2026 | Gonzales Anita Please See Remarks | Tax withheld | 83 | $8.0K |
| Feb 17, 2026 | Gonzales Anita Please See Remarks | Tax withheld | 69 | $6.6K |
| Feb 17, 2026 | Victor Miriame Please See Remarks | Tax withheld | 1,031 | $99.0K |
| Feb 17, 2026 | Vohra Tajinder S Please See Remarks | Tax withheld | 566 | $54.4K |
| Feb 5, 2026 | Goldberg Joel S Please See Remarks | Sale 10b5-1 plan | 532 | $54.5K |
| Feb 5, 2026 | Goldberg Joel S Please See Remarks | Sale 10b5-1 plan | 2,217 | $224.6K |
| Feb 5, 2026 | Singh Prahlad R. Please See Remarks | Sale 10b5-1 plan | 1,307 | $129.4K |
| Feb 5, 2026 | Goldberg Joel S Please See Remarks | Sale 10b5-1 plan | 3,544 | $356.2K |
| Feb 5, 2026 | Goldberg Joel S Please See Remarks | Sale 10b5-1 plan | 6,424 | $639.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for REVVITY, INC.
Free account. Everything above stays public.
Write why you follow REVVITY, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading